Comparison Study of Various Nano Technology Formulation of Curcumin in Treatment of Alzheimer’s Disease
DOI:
https://doi.org/10.22270/ajprd.v8i3.743Keywords:
Alzheimer’s disease, Dementia, Curcumin, Nano Emulsion, Nano Gel, Nano Suspension, Liposomes.Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with cognitive deterioration affecting day to day living and behavioural activities. It is commonest cause of senile and pre-senile dementia. In Alzheimer’s disease, a peptide referred as amyloid beta aggregates (oligomers), and accumulates in the brain to form deposits called as amyloid plaques. According to the world health organization (WHO), 5% of men and 6% of women of above 60 years are victims with Alzheimer’s type dementia globally. In India prevalence of dementia is 33.6%, of which AD contributes approximately 54% and vascular dementia constitutes approximately 39%. Patients with the prolonged use of some Non-steroidal anti-inflammatory (NSAID) drugs such as ibuprofen have lower risk of developing the symptoms of AD; however the chronic use of NSAID can produce a toxic effect on the kidney, liver and GI tract. Recent studies have demonstrated that a curcumin delivery system based on nanoscience and nanotechnology increases the therapeutic potential of this compound. Specifically, several nano-sized carriers such as phospholipid vesicles (liposomes), micelles, solid lipid nanoparticles, polymeric nanoparticles, emulsions, proteins and other molecular complexes have been developed for the efficient delivery of curcumin. Nano particles have demonstrated the enhanced Bioavailability of curcumin including circulation time in the blood. Various nano technology drug delivery system of curcumin showed increased Bio accessibility during treatment of Alzheimer’s disease.
Downloads
References
2. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC. Neurology. 2001; 56(9):1131-2.
3. Sahni JK, Doggui S, Ali J, Baboota S. Alzheimer's disease. J Controlled Rele; 2011; 152(2):208-31.
4. Aynun N, Begum, Mychica R. Jones, Giselle P, Limet. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and alzheimer’s disease. J Pharmacol Exp Ther. 2008; 326(1):196–208.
5. Mishra S, Kalpana, Palanivelu. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Ann Indian Acad Neurol. 2008; 11(1):13–9.
6. Lee W, Loo C, Bebawy M, Luk F, Mason SR, Rohanizadeh R. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Current Neuropharmaco. 2013; 11:338-78.
7. Mahajan YR. Nanotechnology-enhanced curcumin: symbiosis of ancient wisdom of east with modern medical science. Nanotech Insights. 2011; 2:17-27.
8. Ringman JM. A potential role of the curry spice curcumin in alzheimer's disease. Curr Alzheimer Res. 2005; 2(2):131-36.
9. Daniel S. Through metal binding, curcumin protects against lead- and cadmium-induced lipid peroxidation in rat brain homogenates and against lead- induced tissue damage in rat brain. J Inorg Biochem. 2004; 98(2):266-75.
10. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in alzheimer's disease animal models. J Alzheimer's Dis. 2004; 6(4):367-77.
11. Yang F. Curcumin inhibits formation of amyloidbeta oligomers and fibrils, binds plaques, and reduces amyloid in-vivo. J Biol Chem. 2005; 280(7):5892-901.
12. Garcia-Alloza M. Curcumin labels amyloid pathology In-Vivo, disrupts existing plaques and partially restores distorted neurites in an alzheimer mouse model. J Neurochem. 2007; 102(4):1095-104.
13. Ono K. Curcumin has potent anti-amyloidogenic effects for alzheimer's beta fibrils in-vitro. J Neurosci Res. 2004; 75(6):742-50.
14. Mishra S, Palanivelu K. The Effect of curcumin (turmeric) on alzheimer's disease: an overview. Ann Indian Acad Neurol. 2008; 11(1):13-9.
15. Luo Z, Rohan V, Tikekar, Nitin N. Chemistry approach for imaging intracellular and intratissue distribution of curcumin and its nanoscale carrier. Bioconju Chemi. 2014; 25(1):32−42.
16. Pandav R, Belle SH, Dekosky ST. Apolipoprotein E polymorphism and Alzheimer s disease: The Indo-US cross-national dementia study. Arch Neural 2000; 57:824-30.
17. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH. Curry consumption and cognitive function in the elderly. Am J Epidemiol. 2006; 164(9):898-906.
18. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in-vivo.J Biol Chem. 2005; 280(7):5892-901.
19. Elumalai S, Devika R. Biosynthesis of silver nanoparticles using curcuma longa and their antibacterial activity. Int J Pharm Res Sci. 2014; 2(1):98-103.
20. Ravichandran R, Pharmacokinetic study of nanoparticulate curcumin: oral formulation for enhanced bioavailability. J Biomat Nanobiotec. 2013; 4(3):291-99.
21. Sou K. Curcumin towards nano medicine. Recent Patent Nano Medi. 2012; 2(2):133-45.
22. Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. J Biomat Nanobiotech. 2011; 2:626-39.
23. Chime SA, Kenechukwu FC, Attama AA, Nanoemulsions advances in formulation, characterization and applications in drug delivery. Intech.
24. Rachmawati H, Budiputra DK, Suhandono S, Anggadiredja K. Curcumin nanoemulsion for transdermal application:formulation and evaluation, research and development on nanotechnology in Indonesia. 2014;1(1):5-8.
25. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood–brain barrier model and in alzheimer’s disease Tg2576 mice. AAPS J. 2013; 15(2). 324-36.
26. Gonçalves C, Pereira P, Schellenberg P, Coutinho PJ, Gama FM. Self-assembled dextrin nanogel as curcumin delivery system. J Biomater Nanobiotech. 2012; 3(2):178-84.
27. Nazem A, Mansoori GA. Nanotechnology for Alzheimer's disease detection and treatment. Insciences J. 2011; 1(4):169-93.
28. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neuro degenerative diseases (alzheimer’s disease and parkinson’sdisease). J Drug Delivery. 2011.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.